Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 20/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.77 |
| ▸ | MTOR | P42345 | 6/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.72 |
| ▸ | ATR | Q13535 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18824582 | 0.91 | ATM (0.77) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL17246505 | 0.90 | ATM (0.73) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL18843777 | 0.90 | ATM (0.73) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL20006461 | 0.90 | ATM (0.73) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL17245474 | 0.88 | ATM (0.78) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL17272485 | 0.85 | ATM (0.81) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL17272487 | 0.85 | ATM (0.81) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL17241482 | 0.84 | ATM (1.00) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL23634752 | 0.83 | ATM (0.55) | ATMKCNH2MTORPIK3CAATR | |
| SCHEMBL17272570 | 0.83 | ATM (1.00) | ATMKCNH2MTORPIK3CAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185468-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2019-06-20 | — | — | US | disclosed |
| US-10189834-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-01-29 | — | — | US | disclosed |
| US-10189834-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-01-29 | — | — | US | disclosed |
| US-20180134699-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134699-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180134699-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| EP-3140303-B1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| EP-3140303-B1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| US-9822111-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-9822111-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
| US-9428503-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | ASTRAZENECA AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-9428503-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | ASTRAZENECA AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-9428503-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | ASTRAZENECA AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | disclosed |
| WO-2015170081-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134699-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885KCNH2 1895/4885MTOR 393/4885 |
| US-20190185468-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885KCNH2 1895/4885MTOR 393/4885 |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885KCNH2 1895/4885MTOR 393/4885 |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885KCNH2 1895/4885MTOR 393/4885 |
| US-10189834-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, CHEK2, CHEK1 | ATM 1/4885KCNH2 1895/4885MTOR 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.